

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL  
*(Translation of Registrant's name into English)*

68 Xinqing Road  
Suzhou Industrial Park  
Suzhou, Jiangsu  
China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

---

## **EXPLANATORY NOTE**

On February 9, 2026, Ascentage Pharma Group International issued a press releases entitled “Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026”. A copy of the press release is furnished as Exhibit 99.1.

## INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Exhibit Title</b>
99.1	<a href="#">Press Release dated February 9, 2026</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ASCENTAGE PHARMA GROUP INTERNATIONAL**

Date: February 9, 2026

/s/ Dajun Yang

Name: Dajun Yang

Title: Chief Executive Officer



### **Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026**

ROCKVILLE, Md. and SUZHOU, China, February 9, 2026 -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“**Ascentage Pharma**” or the “**Company**,” a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 being held on February 11-12, 2026.

The management team will be participating in a fireside chat at 9:30 am EST on Thursday, February 12<sup>th</sup>. The webcast can be accessed by visiting the Events page in the Investor Relations section of Ascentage’s website.

#### **About Ascentage Pharma**

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, Lisoftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisoftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisoftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.

---

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit <https://ascentage.com/>

### **Forward-Looking Statements**

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled "Risk factors" and "Special note regarding forward-looking statements and industry data" in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed "Forward-looking Statements" and "Risk Factors" in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Contacts**

#### **Investor Relations:**

Yuly Chen, Senior Investor Relations Director  
Ascentage Pharma  
[IR@ascentage.com](mailto:IR@ascentage.com)  
+86 512 85557777  
+1 (301) 792-5658

Stephanie Carrington  
ICR Healthcare  
[AscentageIR@icrhealthcare.com](mailto:AscentageIR@icrhealthcare.com)  
+1 (646) 277-1282

#### **Media Relations:**

Sean Leous  
ICR Healthcare  
[AscentagePR@icrhealthcare.com](mailto:AscentagePR@icrhealthcare.com)  
+1 (646) 866-4012